Atypical diffuse bilateral cystic lung changes secondary to erlotinib treatment in a patient with metastatic non-small cell lung carcinoma: A case report and literature review

Erlotinib is a first-generation epidermal growth factor receptor (EGFR) tyrosine kinase inhibitor (TKI) approved in the first-line treatment of advanced non-small-cell lung cancer (NSCLC) patients with sensitizing epidermal growth factor receptor (EGFR) mutations. The response rate to erlotinib is ~...

Descrizione completa

Salvato in:
Dettagli Bibliografici
Pubblicato in:Mol Clin Oncol
Autori principali: Ansari, Jawaher, Batubara, Enas, Ali, Muhammad, Farrag, Ashraf, Bashir, Farhat, Farghaly, Hussein R., Ali, Arwa M., Shaukat, Arif
Natura: Artigo
Lingua:Inglês
Pubblicazione: D.A. Spandidos 2018
Soggetti:
Articles
Accesso online:https://ncbi.nlm.nih.gov/pmc/articles/PMC6030992/
https://ncbi.nlm.nih.gov/pubmed/29977544
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.3892/mco.2018.1620
Tags: Aggiungi Tag
Nessun Tag, puoi essere il primo ad aggiungerne! !

Documenti analoghi